Australia is urgently seeking clarification on U.S. President Donald Trump's proposed 200% tariffs on pharmaceutical imports, which could severely impact one of Australia's key export sectors. Treasurer Jim Chalmers expressed concern on Wednesday following Trump's announcement of sweeping tariff measures, including a 50% levy on copper imports, during a cabinet meeting.
While copper exports to the U.S. make up less than 1% of Australia's total, the pharmaceutical industry is far more vulnerable. In 2023, Australia exported approximately A$2.1 billion (US$1.37 billion) worth of medicines and pharmaceuticals to the United States, making it one of the nation’s top export categories, according to the Australian Bureau of Statistics.
Chalmers emphasized the seriousness of the issue, stating, “Much more concerning are the developments around pharmaceuticals, and that’s why we’re urgently seeking more detail on what’s been announced.”
Despite growing pressure from U.S. lobby groups, Chalmers reaffirmed that Australia will not use its Pharmaceutical Benefits Scheme (PBS) as a bargaining tool. The PBS, which subsidizes prescription medications for Australians, has been criticized by American pharmaceutical companies as discriminatory and damaging to U.S. exports. However, Chalmers stated, “We’re not willing to compromise the PBS. It’s a crucial part of our healthcare system.”
U.S. trade groups have long targeted the PBS, calling it an “egregious” pricing regime that puts American pharmaceutical firms at a disadvantage. Trump's tariff threat appears to be a direct response to these concerns, raising trade tensions between the two allies.
Australia's government is now working swiftly to engage with U.S. counterparts and gain clarity on the scope and intent of the proposed tariffs, particularly on pharmaceutical products.